相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High plasma homocysteine level is associated with increased prevalence of the non-remission state in rheumatoid arthritis: Findings from the KURAMA cohort
Masao Katsushima et al.
MODERN RHEUMATOLOGY (2023)
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Tadamitsu Kishimoto et al.
ANNUAL REVIEW OF IMMUNOLOGY (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Waiting for JAK inhibitor safety data
Tue Wenzel Kragstrup et al.
RMD OPEN (2022)
Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients
Tomoya Nakajima et al.
RHEUMATOLOGY INTERNATIONAL (2022)
Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort
Ryu Watanabe et al.
IMMUNOLOGICAL MEDICINE (2022)
EULAR definition of difficult-to-treat rheumatoid arthritis
Gyorgy Nagy et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Frances Humby et al.
LANCET (2021)
Tocilizumab can efficiently prevent bone destruction in patients with recent-onset rheumatoid arthritis
Yasuhiko Hirabayashi
MODERN RHEUMATOLOGY (2021)
Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice
Yasuharu Nakashima et al.
MODERN RHEUMATOLOGY (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
Anita Boyapati et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Predicting treatment response to IL6R blockers in rheumatoid arthritis
Bako Nouri et al.
RHEUMATOLOGY (2020)
Predictive factors for structural remission using abatacept: Results from the ABROAD study
Kosaku Murakami et al.
MODERN RHEUMATOLOGY (2019)
Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis
Uri Arad et al.
JOURNAL OF RHEUMATOLOGY (2019)
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review
Atsushi Ogata et al.
MODERN RHEUMATOLOGY (2019)
Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)
Yuko Kaneko et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Rheumatoid arthritis
Josef S. Smolen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan
Tomohiro Koga et al.
PLOS ONE (2017)
Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study
Tadashi Okano et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
Yuko Kaneko et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy
Tomohiro Koga et al.
MEDICINE (2016)
Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group
Yasuhiko Hirabayashi et al.
MODERN RHEUMATOLOGY (2016)
Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index
Shin-ya Kawashiri et al.
Modern Rheumatology (2014)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis
R. J. Maneiro et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2013)
IL-6 plays an essential role in neutrophilia under inflammation
Misato Hashizume et al.
CYTOKINE (2011)
Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study
Tsutomu Takeuchi et al.
RHEUMATOLOGY (2011)
Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort
Michael P. M. van der Linden et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
分享论文
